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ABSTRACT
Considerable evidence from both clinical and experimental studies suggests 
that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), 
are critical in the induction of resistance to enzalutamide and abiraterone. In this 
study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide 
and abiraterone and examined if inhibition of AR-V7 can improve abiraterone 
treatment response. We found that enzalutamide-resistant cells are cross-resistant 
to abiraterone, and that AR-V7 confers resistance to abiraterone. Knock down of 
AR-V7 by siRNA in abiraterone resistant CWR22Rv1 and C4-2B MDVR cells restored 
their sensitivity to abiraterone, indicating that AR-V7 is involved in abiraterone 
resistance. Abiraterone resistant prostate cancer cells generated by chronic treatment 
with abiraterone showed enhanced AR-V7 protein expression. Niclosamide, an FDA-
approved antihelminthic drug that has been previously identified as a potent inhibitor 
of AR-V7, re-sensitizes resistant cells to abiraterone treatment in vitro and in vivo. In 
summary, this preclinical study suggests that overexpression of AR-V7 contributes to 
resistance to abiraterone, and supports the development of combination of abiraterone 
with niclosamide as a potential treatment for advanced castration resistant prostate 
cancer.
INTRODUCTION
Castration resistant prostate cancer (CRPC) 
is characterized by increased activation and/or 
overexpression of androgen receptor (AR) resulting in 
the transcription of downstream target genes and tumor 
progression despite castrate levels of androgen in the 
patient. At this stage of prostate cancer progression, 
there are currently several agents in use to stop or 
reverse tumor growth. Amongst these is abiraterone. 
Abiraterone is a steroidogenesis inhibitor of the androgen 
synthesis pathway and functions by blocking CYP17A1 
activity and preventing the conversion of pregnenolone 
to dihydrotestosterone (DHT) [1, 2]. This results in 
significant loss of androgen production in peripheral 
tissues and loss of production of precursors needed for 
intratumoral androgen synthesis. Recently, abiraterone 
was discovered to be converted by 3β-hydroxysteroid 
dehydrogenase (3β-HSD) to a more active Δ4-abiraterone 
(D4A) form which blocks multiple steroidogenic enzymes 
and antagonizes the androgen receptor [3]. Abiraterone 
treatment in patients who had progressed after docetaxel 
therapy demonstrated a 3.9 month survival benefit and 
chemotherapy-naïve patients had a 4.4 month survival 
benefit with abiraterone [4-6]. It is unfortunate, however, 
that one-third of all patients display primary resistance to 
abiraterone treatment, and all patients with initial response 
progress by 15 months of abiraterone treatment [4].
Although enzalutamide and abiraterone have 
achieved significant outcomes in the clinic [4, 7], the 
controversy of sequential treatment for late stage prostate 
cancer patients remains [8-13]. Moderate effects of 
sequential treatment of enzalutamide and abiraterone in 
clinical patients revealed the existence of cross resistance 
between enzalutamide and abiraterone. This brings to light 
an urgent need to identify the cross resistance mechanisms 
Oncotarget32211www.impactjournals.com/oncotarget
involved in order to discover biomarkers and treatment 
strategies that can overcome the resistance.
Several pathways have been identified which may 
play a role in the development of abiraterone resistance, 
many of which involve re-activation of androgen synthesis 
or changes in androgen receptor signaling [14–18]. Of 
interest in the presented study, is the role of androgen 
receptor variants. These variants are produced due to 
alternative splicing or by genome rearrangement and 
oftentimes result in loss of the AR ligand binding domain 
leading to constitutive activation of the receptor [19–22]. Of 
these variants, androgen receptor variant 7 (AR-V7) is the 
most widely studied and its expression is associated with 
resistance to multiple therapeutics including enzalutamide 
and abiraterone[14, 16, 23–25]. Clinically, Antonarakis et 
al. demonstrated that patients treated with enzalutamide 
or abiraterone that had AR-V7 expression displayed 
significantly lower PSA response, shorter progression-free 
and overall survival compared to men without AR-V7 [26].
Niclosamide, an FDA-approved antihelminthic, 
has been identified as a potent AR-V7 inhibitor in prostate 
cancer cells [27]. Niclosamide promotes AR-V7 protein 
degradation, possibly through activation of the ubiquitin 
proteasome pathway. Furthermore, it reduces AR-V7 
transcriptional activity and reverses enzalutamide resistance 
[27, 28]. However, the experimental evidence of the roles of 
AR-V7 in the responsiveness to abiraterone treatment and 
the effects of niclosamide on abiraterone treatment remain 
unknown. In the present study, we found that enzalutamide-
resistant cells are cross-resistant to abiraterone and that AR-
V7 promotes abiraterone resistance. Abiraterone resistant 
prostate cancer cells generated by chronical treatment with 
abiraterone showed significantly enhanced AR-V7 protein 
expression. Furthermore, niclosamide treatment sensitized 
abiraterone-resistant cells to abiraterone through AR-V7 
inhibition. Of particular importance was the finding that 
niclosamide was capable of reversing abiraterone resistance 
in vivo through the oral administration. This study provides 
insight into prostate cancer cross-resistance and demonstrates 
a novel therapy for overcoming abiraterone resistance by 
niclosamide. Data contained herein are a critical step towards 
the development of treatment strategies for patients with 
advanced castration resistance prostate cancer.
RESULTS
C4-2B MDVR cells are cross resistant to 
abiraterone
In present study, we generated enzalutamide resistant 
C4-2B MDVR cells [29]. C4-2B MDVR cells have high 
expression of AR variants, including AR-V7, compared 
to parental C4-2B cells and expression of these variants 
cannot be inhibited by either abiraterone or enzalutamide 
(Figure 1A). This suggests AR-V7 might be the underlying 
mechanism of cross resistance to both abiraterone and 
enzalutamide. To test this hypothesis, we investigated the 
differences in response to abiraterone between C4-2B parental 
and C4-2B MDVR cells. Both cell lines were treated with 
varying concentrations of abiraterone or enzalutamide for 48 
hours and cell numbers were determined. As shown in Figure 
1B, C4-2B parental cells are sensitive to both abiraterone and 
enzalutamide, while C4-2B MDVR cells showed a reduced 
response to abiraterone and resistance to enzalutamide. 
These results were also confirmed by clonogenic assay. As 
depicted in Figure 1C and 1D, abiraterone and enzalutamide 
significantly inhibited C4-2B parental cell colony formation 
ability while both drugs had limited effects on C4-2B 
MDVR cells. Collectively, the above results suggest a cross 
resistance phenomenon is present between enzalutamide and 
abiraterone.
AR-V7 confers resistance to abiraterone in 
prostate cancer
To further examine the sensitivity of prostate cancer 
cells to abiraterone, LNCaP, C4-2B and CWR22Rv1 cells 
were treated with different concentrations of abiraterone for 
48 hours. CWR22Rv1 cells are more resistant to abiraterone 
treatment than LNCaP and C4-2B cells (Figure 2A). The 
AR-V7 expression was examined by western blot. As shown 
in Figure 2B, CWR22Rv1 cells express significantly higher 
AR-V7 than LNCaP and C4-2B cells. Previous studies have 
shown that AR-V7 might be an important player for driving 
enzalutamide resistance in prostate cancer cells [24, 27]. 
To examine whether it also induces abiraterone resistance, 
CWR22Rv1 and C4-2B MDVR cells were transiently 
transfected with AR-V7 siRNA and subsequently treated 
with 10 μM abiraterone for 3 days. As shown in Figure 2C, 
knockdown of AR-V7 significantly enhanced abiraterone 
treatment in both CWR22Rv1 and C4-2B MDVR cells. The 
effects of AR-V7 knockdown were examined by western 
blot (Figure 2D). To determine whether overexpression of 
AR-V7 confers resistance to abiraterone, we generated AR-
V7 overexpressing C4-2 AR-V7 cells by stably expressing 
AR-V7 in C4-2 cells. C4-2 neo and C4-2 AR-V7 were 
treated with different concentrations of abiraterone for 48 
hours and cell numbers were determined. C4-2 AR-V7 cells 
exhibited resistance to abiraterone treatment compared to 
C4-2 neo cells (Figure 2E). Abiraterone inhibits full length 
AR but not AR-V7 expression in C4-2 AR-V7 cells (Figure 
2F). These results demonstrate that overexpression of AR-
V7 confers resistance to abiraterone in prostate cancer cells.
Niclosamide inhibits AR-V7 expression and 
enhances abiraterone treatment in vitro
Having demonstrated that AR-V7 also confers 
resistance to abiraterone treatment, we next determined 
whether niclosamide improves abiraterone treatment by 
inhibition of AR-V7 expression in prostate cancer cells. 
To examine if niclosamide enhances abiraterone treatment 
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in vitro, CWR22Rv1 or C4-2B MDVR cells were treated 
with 0.5 μM niclosamide with or without 10 μM abiraterone 
for 2 days and total cell numbers were counted. As shown in 
Figure 3A and 3B, 10 μM abiraterone had limited effects on 
cell growth, 0.5 μM niclosamide inhibited cell growth, and the 
combination treatment significantly inhibited cell growth more 
than either treatment on its own. The results were confirmed by 
clonogenic assay: combination of niclosamide with abiraterone 
significantly inhibited colony number and reduced colony size 
in CWR22Rv1 and C4-2B MDVR cells (Figure 3C). Western 
blots were performed to determine if combination treatment 
with niclosamide and abiraterone inhibit AR-V7 expression. 
As shown in Figure 3D, 0.5 μM niclosamide inhibited AR-
V7 protein expression but had only moderate effects on full 
length AR. Combined niclosamide and abiraterone treatment 
not only further inhibited AR variants expression, but also 
inhibited full length AR expression in both CWR22Rv1 and 
C4-2B MDVR cells. Taken together, these results suggest 
niclosamide can enhance abiraterone treatment by inhibition 
of AR-V7 expression in vitro.
C4-2B abiraterone resistant cells generated by 
chronic treatment with abiraterone showed 
enhanced expression of AR-V7
To further examine that AR-V7 confers abiraterone 
resistance, we generated an abiraterone resistant prostate 
cancer cell line by continuous culture of C4-2B cells in media 
containing abiraterone acetate. As shown in Figure 4A, after 
12 months of being cultured in abiraterone acetate containing 
medium, C4-2B AbiR (C4-2B abiraterone resistant) cells 
developed resistance to abiraterone acetate. Abiraterone 
acetate at 5 μM significantly suppressed the growth of C4-
2B parental cells, but had limited effects on C4-2B AbiR 
cells. We then examined the AR-V7 levels in C4-2B AbiR 
cells. As shown in Figure 4B, C4-2B AbiR cells express 
significantly higher levels of AR-V7 protein compared to 
C4-2B parental cells. Knock down of AR-V7 expression 
significantly re-sensitized C4-2B AbiR cells to abiraterone 
acetate (Figure 4C). To find out if niclosamide could enhance 
abiraterone treatment in C4-2B AbiR cells, C4-2B AbiR cells 
were treated with DMSO, 5 μM abiraterone acetate, 0.5 μM 
niclosamide or their combination for 48 hours. Niclosamide 
significantly suppressed cell growth in C4-2B AbiR cells, 
while combination treatment further enhanced the effects 
(Figure 4D). The results were also confirmed by clonogenic 
assay (Figure 4E). Niclosamide significantly inhibited AR-
V7 expression, combination of abiraterone and niclosamide 
further suppressed both full-length AR and AR-V7 expression 
in C4-2B AbiR cells (Figure 4F).
Niclosamide synergizes abiraterone treatment 
in vivo through the oral administration
To test the combination effects in vivo, a CWR22Rv1 
xenograft model was used. Mice were treated with 
abiraterone acetate, niclosamide or their combination 
through oral administration. As shown in Figure 5A–5D, 
Figure 1: Enzalutamide resistant prostate cancer cells are cross resistant to abiraerone. A. C4-2B parental and C4-2B 
MDVR cells were treated with different dose of abiraterone (5μM, 10 μM and 20 μM) or enzalutamide (10 μM and 20 μM) and total 
cell lysates were harvested and subjected to western blot. B. C4-2B parental and C4-2B MDVR cells were treated with different doses 
of abiraterone (5μM, 10 μM and 20 μM) or enzalutamide (10 μM and 20 μM) for 48 hours and total cell numbers were counted and cell 
survival rate was calculated. C. Colonogenic assay was performed. Pictures were taken under microscope (inside panel). D. The colonies 
were counted and results are presented as means ± SD of 2 experiments performed in duplicate. Results for other panels are presented as 
means ± SD of 3 experiments performed in duplicate. *P<0.05
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Figure 2: AR-V7 confers abiraterone resistance in prostate cancer. A. CWR22Rv1, C4-2B and LNCaP cells were treated 
with different concentrations of abiraterone for 48 hours, total cell numbers were counted and cell survival rate was calculated. B. whole 
cell lysates from LNCaP, C4-2B and CWR22Rv1cells were extracted, AR-V7 and full length AR were examined by western blot. C–D. 
CWR22Rv1 or C4-2B MDVR cells were transiently transfected with AR-V7 siRNA and then treated with 10 μM abiraterone for 3 days, 
total cell numbers were counted and cell survival rate (%) was calculated and the AR-V7 knock down efficiency was examined by western 
blot. E. C4-2 neo or C4-2 AR-V7 cells were treated with different concentrations of abiraterone for 48 hours, total cell numbers were 
counted and cell survival rate (%) was calculated. F. C4-2 neo or C4-2 AR-V7 cells were treated with different concentration of abiraterone 
for 48 hours, whole cell lysates were subjected to western blot. Results are presented as means ± SD of 3 experiments performed in 
duplicate. *P<0.05 Abi: Abiraterone.
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Figure 3: Niclosamide enhanced abiraterone treatment in vitro. A–B. CWR22Rv1 cells or C4-2B MDVR cells were treated with 
0.5 μM niclosamide with or without 10 μM abiraterone in media containing FBS and cell numbers were counted after 48 hours. Results are 
presented as means ± SD of 3 experiments performed in duplicate. C. Clonogenic assays were performed. Colonies numbers were counted 
and results are presented as means ± SD of 2 experiments performed in duplicate. D. CWR22Rv1 and C4-2B MDVR cells were treated 
with DMSO, 10 μM abiraterone, 0.5 μM niclosamide or combination for 48 hours, total cell lysates were collected and subjected to western 
blot. *P<0.05 Abi: Abiraterone. Nic: Niclosamide.
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Figure 4: C4-2B cells chronically treated with abiraterone acetate express AR-V7. A. C4-2B parental and C4-2B AbiR 
cells were treated with different concentrations abiraterone acetate for 3 days, total cell number was counted and cell survival rate was 
calculated. B. C4-2B parental, C4-2B AbiR, C4-2B MDVR and CWR22Rv1 cells were cultured in media containing FBS for 3 days, total 
cell lysates were collected and subjected to western blot. C. C4-2B were transiently transfected with AR-V7 siRNA and then treated with 
5 μM abiraterone acetate for 3 days. Total cell numbers were counted and cell survival rate (%) was calculated. The AR-V7 knock down 
efficiency was examined by western blot. D. C4-2B AbiR cells were treated with 0.5 μM niclosamide with or without 5 μM abiraterone 
acetate in media containing FBS and cell numbers were counted after 48 hours. Results are presented as means ± SD of 3 experiments 
performed in duplicate. E. C4-2B AbiR cells were treated with 0.5 μM niclosamide with or without 5 μM abiraterone acetate in media 
containing FBS and clonogenic assays were performed, colony pictures were taken under microscope. F. C4-2B AbiR cells were treated 
with DMSO, 5 μM abiraterone acetate, 0.5 μM niclosamide or combination for 48 hours. Total cell lysates were collected and subjected to 
western blot. *P<0.05 Abi-acetate: Abiraterone acetate. Nic: Niclosamide.
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Figure 5: Niclosamide enhanced abiraterone treatment in vivo. A. Mice bearing CWR22Rv1 xenografts were treated with 
vehicle control, abiraterone acetate (200mg/Kg orally), niclosamide (500 mg/Kg orally) or their combination for 3 weeks, tumor volumes 
were measured twice every week and the tumors were collected. B. Pictures of tumors from each group were taken after 3 weeks treatment. 
C–D. Each group tumor weight and body weight were measured and averaged. E. Ki67 was analyzed in tumor tissues by IHC staining and 
quantified as described in methods. *P<0.05 Abi-Acetate: Abiraterone Acetate.
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CWR22Rv1 tumors were resistant to abiraterone and 
treatment with niclosamide alone inhibited tumor growth. 
However, combination of niclosamide with abiraterone 
synergistically inhibited tumor size and tumor weight without 
decreasing mouse body weights. The cell proliferation rate 
of tumor samples was analyzed by IHC for Ki67 expression. 
Niclosamide inhibited Ki67 expression while combination 
treatment with abiraterone further decreased Ki67 expression 
(Figure 5E). These data demonstrate that niclosamide 
synergizes with abiraterone treatment in abiraterone resistant 
CWR22Rv1 tumor models through oral administration, and 
suggest that inhibiting AR-V7 with niclosamide is a potent 
treatment strategy for advanced prostate cancer.
DISCUSSION
Since abiraterone and enzalutamide were approved 
by the FDA, the great potential to extend the lives and 
improve the quality of advanced prostate cancer patients 
is on horizon. Unfortunately, resistance to abiraterone 
and enzalutamide occurs frequently and there is still no 
definitive cure for metastatic CRPC patients. Considerable 
evidence from both clinical and experimental studies 
suggests that androgen receptor variants, particularly AR-
V7, play vital roles in the development of resistance to 
enzalutamide as well as abiraterone therapy [14, 16, 23-
26]. In the present study, we demonstrated that AR-V7 
confers resistance to abiraterone and that niclosamide, 
a previously identified potent inhibitor of AR-V7, 
re-sensitizes resistant cells to abiraterone treatment. 
Furthermore, niclosamide synergizes with abiraterone 
treatment both in vitro and in vivo.
Both abiraterone and enzalutamide are FDA 
approved drugs. When prostate cancer becomes resistant 
to one drug, the subsequent response rate to the other drug 
is 20% or less [8, 30, 31], suggesting cross-resistance 
exists between these two drugs. However, the underlying 
mechanisms are incompletely understood. The role 
of AR splice variants in CRPC has been functionally 
characterized in recent years due to their prevalence in 
advanced prostate cancer tissues [21, 32, 33]. Truncated 
AR variants including AR-V7 have been suggested to drive 
castration resistant growth and AR target genes expression 
leading to resistance to enzalutamide [23, 24]. In the 
present study, we showed that cells which are resistant 
to enzalutamide are also resistant to abiraterone, and that 
AR-V7 overexpression confers resistance to abiraterone. 
Chronic treatment of C4-2B cells with abiraterone 
significantly induced AR-V7 protein expression; while 
overexpression of AR-V7 in C4-2 cells drives these cells 
become resistant to abiraterone. Knock down of AR-V7 
expression by siRNA in CWR22Rv1, C4-2B MDVR and 
C4-2B AbiR cells significantly restored their sensitivity 
to abiraterone treatment, suggesting that AR-V7 plays an 
important role in the development of abiraterone resistance 
in addition to enzalutamide resistance.
Abiraterone inhibits CYP17A1 and reduces 
circulating androgen levels that activate the full length 
AR. A recent report also showed that abiraterone could be 
converted to D4A, a more active form which antagonizes 
full length AR directly [3]. While AR-V7 overexpression 
confers resistance to current anti-androgen therapies, AR-
V7 is not suppressed by abiraterone. Therefore, there is an 
urgent need to develop novel agents that inhibit AR-V7 to 
overcome drug resistance. Our previous studies identified 
niclosamide as a potent inhibitor of AR-V7, and found 
that it significantly enhances enzalutamide treatment both 
in vitro and in vivo [27]. Niclosamide is an FDA approved 
drug for the treatment of human tapeworm infection and 
has rich repository of pharmacokinetic data [34-36]. 
Niclosamide has been proven to be safe and has very 
low toxicity in patients [37-41], and therapeutic blood 
concentrations can be achieved through oral administration 
using FDA approved administration dose. In the present 
study, we showed that niclosamide enhanced abiraterone 
treatment through oral administration in prostate 
cancer xenograft model, suggesting the combination of 
niclosamide and abiraterone warrants clinical investigation 
to treat advanced prostate cancer patients.
Taken together, we found that AR-V7 is involved 
in the cross resistance of enzalutamide and abiraterone. 
Targeting AR-V7 by siRNA or inhibition of protein 
expression by niclosamide can significantly enhance 
abiraterone treatment in vitro and in vivo. These data 
support the combination of abiraterone and niclosamide 
as a potential treatment for advanced prostate cancer.
MATERIALS AND METHODS
Reagents and cell culture
LNCaP, C4-2, C4-2B and CWR22Rv1 cells were 
maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), 100 units/ml penicillin and 0.1 
mg/ml streptomycin. C4-2-neo and C4-2 AR-V7 cells 
were generated by stable transfection of C4-2 cells with 
either empty vector pcDNA3.1 or pcDNA3.1 encoding 
AR-V7 and were maintained in RPMI1640 medium 
containing 300 μg/mL G418. C4-2B MDVR (C4-2B 
enzalutamide resistant) cells were described previously 
[29]. C4-2B MDVR cells were maintained in 20 μM 
enzalutamide containing medium. C4-2B AbiR (C4-2B 
abiraterone resistant) cells were cultured in 5-20 μM 
abiraterone acetate over 12 months and maintained in 10 
μM abiraterone acetate containing medium. All cells were 
maintained at 37°C in a humidified incubator with 5% 
carbon dioxide.
Plasmids transfection and luciferase assay
For small interfering RNA (siRNA) transfection, 
cells were seeded at a density of 1×105 cells per well in 
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12-well plates or 3×105 cells per well in 6-well plates and 
transfected with siRNA (Dharmacon) targeting the AR-
V7 sequence (GUAGUUGUAAGUAUCAUGA) [42] or 
a control siRNA targeting the luciferase (Luc) gene, non-
targeting siRNA control (CTTACGCTGAGTACTTCGA), 
using Lipofectamine 2000 (Invitrogen).
Western blot analysis
Cellular protein extracts were resolved on SDS–
PAGE and proteins were transferred to nitrocellulose 
membranes. After blocking for 1 hour at room temperature 
in 5% milk in PBS/0.1% Tween-20, membranes were 
incubated overnight at 4°C with the indicated primary 
antibodies [AR441, (SC-7305, Santa Cruz Biotechnology, 
Santa Cruz, CA); AR-V7 (AG10008, Precision antibody); 
Tubulin (T5168, Sigma-Aldrich, St. Louis, MO)]. Tubulin 
was used as loading control. Following secondary 
antibody incubation, immunoreactive proteins were 
visualized with an enhanced chemiluminescence detection 
system (Millipore, Billerica, MA) [43].
Cell growth assay
C4-2B parental or C4-2B MDVR cells were seeded 
on 12-well plates at a density of 1×105 cells/well in 
RPMI 1640 media containing 10% FBS and treated with 
varying concentrations of abiraterone or enzalutamide 
for 48 hours; C4-2 neo, C4-2 AR-V7, LNCaP, C4-2B or 
CWR22Rv1 cells were treated with varying concentrations 
of abiraterone for 48 hours; CWR22Rv1, C4-2B MDVR 
or C4-2B AbiR cells were transiently transfected with 
siRNA targeting AR-V7 or a control siRNA, followed 
by treatment with abiraterone for 3 days. CWR22Rv1 
cells, C4-2B MDVR or C4-2B AbiR cells were seeded 
on 12-well plates at a density of 0.5×105 cells/well in 
RPMI 1640 media containing 10% FBS and co-treated 
with niclosamide and abiraterone in media containing 
FBS for 2 days. Total cell numbers were counted and the 
cell survival rate (%) was calculated. Cell survival rate 
(%) = (Treatment group cell number / Control group cell 
number) ×100%.
Clonogenic assay
C4-2B parental or C4-2B MDVR cells were treated 
with DMSO, 5 μM, 10 μM or 20 μM abiraterone, or 10 
μM or 20 μM enzalutamide in media containing 10% 
complete FBS. CWR22Rv1 cells, C4-2B MDVR or C4-2B 
AbiR cells were treated with niclosamide with or without 
abiraterone. Cells were plated at equal densities (2000 
cells/dish) in 100 mm dishes for 14 days; the medium was 
changed every 7 days. The colonies were rinsed with PBS 
before staining with 0.5% crystal violet/4% formaldehyde 
for 30 min and the numbers of colonies were counted as 
described previously [44].
In vivo tumorigenesis assay
CWR22Rv1 cells (4 million) were mixed with 
matrigel (1:1) and injected subcutaneously into the 
flanks of 6-7 week male SCID mice. Tumor-bearing 
mice (tumor volume around 50-100 mm3) were 
randomized into four groups (5 mice each group) and 
treated as follows: (1) vehicle control (0.5% weight/
volume (w/v) Methocel A4M through oral), (2) 
Abiraterone acetate (200 mg/kg, through oral), (3) 
Niclosamide (500 mg/kg, through oral), (4) Abiraterone 
acetate (200 mg/kg, through oral) + Niclosamide 
(500 mg/kg, through oral). Tumors were measured 
using calipers twice a week and tumor volumes were 
calculated using length × width2/2. Tumor tissues were 
harvested after 3 weeks of treatment.
Immunohistochemistry
Tumors were fixed by formalin and paraffin 
embedded. Tissue sections were dewaxed, rehydrated, 
and blocked for endogenous peroxidase activity. Antigen 
retrieval was performed in sodium citrate buffer (0.01 
mol/L, pH 6.0) in a microwave oven at 1,000 W for 3 
min and then at 100 W for 20 min. Nonspecific antibody 
binding was blocked by incubating slides in 10% fetal 
bovine serum in PBS for 30 min at room temperature. 
Slides were then incubated with anti-Ki-67 (at 1:500; 
NeoMarker) at room temperature for 30 min. Slides 
were then washed and incubated with biotin-conjugated 
secondary antibodies for 30 min, followed by incubation 
with avidin DH-biotinylated horseradish peroxidase 
complex for 30 min (Vectastain ABC Elite Kit, Vector 
Laboratories). The sections were developed with the 
diaminobenzidine substrate kit (Vector Laboratories) and 
counterstained with hematoxylin. Nuclear staining of 
cells was scored and counted in 5 different areas of the 
tissue section. Images were taken with an Olympus BX51 
microscope equipped with DP72 camera.
Statistical analysis
All data are presented as means ± standard deviation 
of the mean (SD). Statistical analyses were performed 
with Microsoft Excel analysis tools. Differences between 
individual groups were analyzed by one-way analysis of 
variance (ANOVA) followed by the Scheffé procedure for 
comparison of means. P < 0.05 was considered statistically 
significant.
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